Visfatin Enhances RANKL-Induced Osteoclastogenesis In Vitro: Synergistic Interactions and Its Role as a Mediator in Osteoclast Differentiation and Activation
2024
Visfatin Enhances Osteoclast Formation
publication
10 minutes
Evidence: moderate
Author Information
Author(s): Ok Chang Youp, Kwon Ryuk Jun, Jang Hye-Ock, Bae Moon-Kyoung, Bae Soo-Kyung
Primary Institution: Pusan National University
Hypothesis
Does visfatin enhance RANKL-induced osteoclastogenesis?
Conclusion
Visfatin significantly enhances RANKL-induced osteoclast differentiation and activation in vitro.
Supporting Evidence
- Visfatin treatment increased the number of TRAP-positive osteoclasts.
- Co-treatment with visfatin and RANKL led to enhanced osteoclast differentiation.
- Neutralizing visfatin reduced RANKL-induced osteoclastogenesis.
Takeaway
Visfatin helps bone cells called osteoclasts grow and work better, which is important for bone health.
Methodology
The study used bone marrow-derived macrophages (BMDMs) to assess the effects of visfatin on osteoclast differentiation induced by RANKL.
Limitations
The study was conducted in vitro, which may not fully represent in vivo conditions.
Statistical Information
P-Value
p<0.05
Statistical Significance
p<0.05
Digital Object Identifier (DOI)
Want to read the original?
Access the complete publication on the publisher's website